Paolo De Luca Sells 13,835 Shares of Organigram Holdings Inc. (TSE:OGI) Stock

Market Beat
2024.09.13 20:36
portai
I'm PortAI, I can summarize articles.

Paolo De Luca, a Senior Officer at Organigram Holdings Inc. (TSE:OGI), sold 13,835 shares of the company's stock on September 11th at an average price of C$0.54, totaling C$7,440.90. Post-sale, he owns 625 shares valued at approximately C$587.50. Previously, on August 16th, he sold 10,266 shares at C$0.76. Organigram's stock performance shows a market cap of C$68 million, with a PE ratio of -1.00 and a 52-week range of C$0.35 to C$0.95. Analysts have mixed ratings on the stock, with some lowering and others raising price targets.

Organigram Holdings Inc. (TSE:OGI - Get Free Report) Senior Officer Paolo De Luca sold 13,835 shares of the firm's stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of C$2.54, for a total value of C$35,140.90. Following the completion of the sale, the insider now directly owns 625 shares of the company's stock, valued at approximately C$1,587.50.

Paolo De Luca also recently made the following trade(s):

  • On Friday, August 16th, Paolo De Luca sold 10,266 shares of Organigram stock. The stock was sold at an average price of C$2.76, for a total value of C$28,334.16.

Organigram Stock Performance

OGI stock traded up C$0.04 during midday trading on Friday, reaching C$2.53. The stock had a trading volume of 258,414 shares, compared to its average volume of 319,274. The firm has a fifty day simple moving average of C$2.37 and a two-hundred day simple moving average of C$2.51. The stock has a market cap of C$274.68 million, a PE ratio of -1.00, a P/E/G ratio of 0.42 and a beta of 1.13. The company has a debt-to-equity ratio of 1.13, a quick ratio of 2.62 and a current ratio of 6.95. Organigram Holdings Inc. has a 52-week low of C$1.35 and a 52-week high of C$3.95.

Organigram (TSE:OGI - Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported C$0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of C($0.07) by C$0.10. Organigram had a negative net margin of 153.80% and a negative return on equity of 54.53%. The firm had revenue of C$41.06 million during the quarter, compared to analysts' expectations of C$39.20 million. As a group, equities research analysts anticipate that Organigram Holdings Inc. will post 0.1735254 EPS for the current year.

Analyst Ratings Changes

OGI has been the subject of several recent analyst reports. Jefferies Financial Group lowered their price target on Organigram from C$4.40 to C$4.35 in a report on Friday, May 17th. Canaccord Genuity Group raised their target price on Organigram from C$3.25 to C$3.60 and gave the stock a "speculative buy" rating in a research note on Wednesday, August 14th.

Check Out Our Latest Research Report on Organigram

Organigram Company Profile

(Get Free Report)

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.

Featured Stories

  • Five stocks we like better than Organigram
  • What is a support level?
  • Powering Your Portfolio: The Utility Sector's Electrifying Surge
  • Are Penny Stocks a Good Fit for Your Portfolio?
  • Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
  • When to Sell a Stock for Profit or Loss
  • Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ Invest before this deal closes on 9/18 (From Deal Maker) (Ad)

Should you invest $1,000 in Organigram right now?

Before you consider Organigram, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.

While Organigram currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.